These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 23413806)

  • 21. Residual C-peptide in type 1 diabetes: what do we really know?
    VanBuecken DE; Greenbaum CJ
    Pediatr Diabetes; 2014 Mar; 15(2):84-90. PubMed ID: 24645775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.
    Zaccardi F; Webb DR; Yates T; Davies MJ
    Postgrad Med J; 2016 Feb; 92(1084):63-9. PubMed ID: 26621825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes.
    Koga M; Murai J; Saito H; Kasayama S
    Diabetes Care; 2010 Feb; 33(2):270-2. PubMed ID: 19846794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Insulin secretion and insulin resistance in patients failing to respond to oral hypoglycemic agents].
    Caputo S; Bertoli A; Marini MA; Santini G; Ghirlanda G; Greco AV
    Minerva Endocrinol; 1988; 13(3):167-72. PubMed ID: 3146014
    [No Abstract]   [Full Text] [Related]  

  • 25. Reevaluation of urine C-peptide as measure of insulin secretion.
    Tillil H; Shapiro ET; Given BD; Rue P; Rubenstein AH; Galloway JA; Polonsky KS
    Diabetes; 1988 Sep; 37(9):1195-201. PubMed ID: 3044885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy - A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults.
    Fritsche A
    Exp Clin Endocrinol Diabetes; 2023 Sep; 131(9):500-503. PubMed ID: 37308105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes.
    Wang Y; Gao Y; Cai X; Chen L; Zhou L; Ma Y; Gong S; Han X; Ji L
    J Diabetes Res; 2019; 2019():1747684. PubMed ID: 31485449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.
    Gjessing HJ; Matzen LE; Faber OK; Frøland A
    Diabetologia; 1989 May; 32(5):305-11. PubMed ID: 2666217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Minidiab test to assess the functional state of pancreatic beta-cells in the children of diabetics].
    Gasparian EG; Nersesian SA; Volkova EA; Kriuchkova ZV; Velikanova LI
    Probl Endokrinol (Mosk); 1994; 40(6):7-10. PubMed ID: 7740043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The endogenous insulin secretion was suppressed during insulin therapy in NIDDM patients.
    Murayama Y; Kawai K; Nakamura S; Yamashita K
    Diabetes Res Clin Pract; 1990; 9(2):129-36. PubMed ID: 2198153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-dependent diabetes mellitus: pathophysiology.
    Gerich JE
    Mayo Clin Proc; 1986 Oct; 61(10):787-91. PubMed ID: 3528691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
    Palmer JP; Fleming GA; Greenbaum CJ; Herold KC; Jansa LD; Kolb H; Lachin JM; Polonsky KS; Pozzilli P; Skyler JS; Steffes MW
    Diabetes; 2004 Jan; 53(1):250-64. PubMed ID: 14693724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma and urinary C-peptide in the classification of adult diabetics.
    Koskinen P; Viikari J; Irjala K; Kaihola HL; Seppälä P
    Scand J Clin Lab Invest; 1986 Nov; 46(7):655-63. PubMed ID: 3538365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual B-cell function in insulin dependent (Type 1) and non insulin-dependent (Type 2) diabetics (relationship between 24-hour C-peptide excretion and the clinical features of diabetes).
    Gerö L; Korányi L; Tamás G
    Diabete Metab; 1983 Sep; 9(3):183-7. PubMed ID: 6360742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [C-peptide in the insulin-dependent diabetic].
    Canivet B; Costet C; Faraill MM; Steve JM; Freychet P
    Presse Med; 1984 Jun; 13(24):1495-7. PubMed ID: 6234520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of insulin administration during the mixed meal tolerance test.
    Besser RE; Jones AG; McDonald TJ; Shields BM; Knight BA; Hattersley AT
    Diabet Med; 2012 Oct; 29(10):1279-84. PubMed ID: 22435709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum free C-peptide response to oral glucose loading as a parameter for the monitoring of pancreatic B-cell function in diabetic patients.
    Hsieh SD; Kanazawa Y; Akanuma Y
    Diabetes Res Clin Pract; 1985 Aug; 1(2):109-14. PubMed ID: 3915258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
    Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity.
    Koskinen PJ; Viikari JS; Irjala KM
    Diabetes Care; 1988 Apr; 11(4):318-22. PubMed ID: 3042307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The natural history of diabetes with respect to disorders of insulin function].
    Dorner M; Pinget M; Brogard JM; Sapin R; Paris-Bockel D; Levy P; Jung C
    Journ Annu Diabetol Hotel Dieu; 1984; ():51-71. PubMed ID: 6399540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.